Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013-Reference-Cited by-同舟云学术

Consenso español actualizado sobre el uso del natalizumab (Tysabri®)-2013

Published:2015-06 Issue:5 Volume:30 Page:302-314
ISSN:0213-4853
Container-title:Neurología
language:es
Short-container-title:Neurología

Author:

Fernández O.,García-Merino J.A.,Arroyo R.,Álvarez-Cermeño J.C.,Izquierdo G.,Saiz A.,Olascoaga J.,Rodríguez-Antigüedad A.,Prieto J.M.,Oreja-Guevara C.,Hernández M.A.,Moral E.,Meca J.,Montalbán X.

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference58 articles.

1. Spanish consensus on the use of natalizumab (Tysabri®)--2011;Fernández;Neurologia,2012

2. Ficha técnica de natalizumab 2013. Agencia Europea de Medicamentos [consultado 29 Sep 2013]. Disponible en: http://www.ema.europa.eu

3. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study;Havrdova;Lancet Neurol,2009

4. Natalizumab treatment of multiple sclerosis in Spain: Results of an extensive observational study;Fernández;J Neurol,2012

5. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis;Prosperini;J Neurol Sci,2012

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain;PharmacoEconomics - Open;2023-02-21

2. Clinical and radiological effectiveness of natalizumab extended dosage interval in patients with relapsing multiple sclerosis;REV NEUROLOGIA;2022

3. Evolución de una serie de pacientes con esclerosis múltiple remitente-recurrente tratados con natalizumab durante 7 años mediante el parámetro no evidencia enfermedad activa;Neurología;2021-06

4. Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the “no evidence of disease activity” parameter;Neurología (English Edition);2020-02

5. Monoclonal Antibody Therapy and Long-term Outcomes in Multiple Sclerosis – The Challenge of Treatment Optimisation;European Neurological Review;2018